ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
- PMID: 16832357
- DOI: 10.1038/ng1837
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
Abstract
We screened individuals from 443 familial breast cancer pedigrees and 521 controls for ATM sequence variants and identified 12 mutations in affected individuals and two in controls (P = 0.0047). The results demonstrate that ATM mutations that cause ataxia-telangiectasia in biallelic carriers are breast cancer susceptibility alleles in monoallelic carriers, with an estimated relative risk of 2.37 (95% confidence interval (c.i.) = 1.51-3.78, P = 0.0003). There was no evidence that other classes of ATM variant confer a risk of breast cancer.
Similar articles
-
Cancer risks and mortality in heterozygous ATM mutation carriers.J Natl Cancer Inst. 2005 Jun 1;97(11):813-22. doi: 10.1093/jnci/dji141. J Natl Cancer Inst. 2005. PMID: 15928302
-
Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.Carcinogenesis. 2007 May;28(5):1040-5. doi: 10.1093/carcin/bgl237. Epub 2006 Dec 13. Carcinogenesis. 2007. PMID: 17166884
-
Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia.Br J Cancer. 2005 Jul 25;93(2):260-5. doi: 10.1038/sj.bjc.6602658. Br J Cancer. 2005. PMID: 15942625 Free PMC article.
-
The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants.Cancer Lett. 2005 Sep 28;227(2):105-14. doi: 10.1016/j.canlet.2004.12.001. Epub 2005 Jan 8. Cancer Lett. 2005. PMID: 16112413 Review.
-
ATM and breast cancer susceptibility.Oncogene. 2006 Sep 25;25(43):5906-11. doi: 10.1038/sj.onc.1209873. Oncogene. 2006. PMID: 16998505 Review.
Cited by
-
Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment.Cell Biosci. 2020 Jun 18;10:81. doi: 10.1186/s13578-020-00442-y. eCollection 2020. Cell Biosci. 2020. PMID: 32566127 Free PMC article. Review.
-
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Oncotarget. 2017 Jan 10;8(2):1957-1971. doi: 10.18632/oncotarget.12699. Oncotarget. 2017. PMID: 27779110 Free PMC article.
-
Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.Pharmgenomics Pers Med. 2020 Jul 27;13:227-238. doi: 10.2147/PGPM.S233485. eCollection 2020. Pharmgenomics Pers Med. 2020. PMID: 32801835 Free PMC article. Review.
-
Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.Sci Rep. 2021 Jun 14;11(1):12491. doi: 10.1038/s41598-021-91971-0. Sci Rep. 2021. PMID: 34127761 Free PMC article.
-
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.J Exp Clin Cancer Res. 2024 Aug 21;43(1):236. doi: 10.1186/s13046-024-03143-3. J Exp Clin Cancer Res. 2024. PMID: 39164784 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous